EUROIMMUN’s test detects SARS-CoV-2 antibodies from dried blood spots
Anti-SARS-CoV-2 antibodies can be determined quickly and efficiently in capillary blood (dried blood spots) using the CE-marked test and automation systems from EUROIMMUN.
The Blood Collection Set enables fast and convenient collection of blood from the fingertip by patients or healthcare professionals. The card containing the dried blood spots is then sent to a diagnostic lab without the need for cooling.
For the serological analysis EUROIMMUN exclusively offers two ELISAs for detection of IgG antibodies against the spike protein S1 domain or against modified nucleocapsid protein (NCP). The S1 antigen includes the immunologically relevant receptor binding domain, which is a key target of neutralisation antibodies.
Results obtained with the S1-based ELISA correlate well with those of neutralisation tests. NCP is the most immunodominant antigen of coronaviruses. The antigen used in the ELISA has been modified to contain only the diagnostically relevant epitopes, thus providing optimised performance.
The S1- and NCP-based IgG ELISAs demonstrate specificities of 99.6% and 99.8% and sensitivities of 94.4% and 94.6% respectively.
Parallel use of both ELISAs maximises the accuracy of SARS-CoV-2 antibody detection and can support determination of the SARS-CoV-2 antibody status before and after administration of future S1-based vaccines or antibody therapies.
The ELISAs can be processed automatically with high throughput on the EUROLab- Workstation ELISA. During processing the samples are clearly identified by means of barcodes ensuring a smooth traceable workflow. The dried blood spot analysis enriches EUROIMMUN’s portfolio for COVID-19 diagnostics, which also includes IgM and IgA ELISAs, as well as the EURORealTime SARS-CoV-2 for sensitive direct virus detection by PCR.
For more information, visit: www.coronavirus-diagnostics.com